Skip to main content

Table 3 Risk factors for positive seroconversion of HBsAg in HBsAg-negative patients detected during diagnosis of hematological malignancy

From: Hepatitis B reactivation among 1962 patients with hematological malignancy in Taiwan

  Positive
Sero-
conversion
(n = 41)
No
conversion (n = 1635)
Univariate
P value
Multivariate P value Odds ratio
(95% CI)
Age    0.174 NA  
65 years 12 466    
  < 65 years 29 1169    
Gender    0.737 NA  
 Men 22 866    
 Women 19 769    
Hematological malignancy    0.038 0.084 NA
 AML 5 526    
 ALL 7 140    
 Lymphoma 24 603    
 CML/MPN 0 54    
 CLL 1 21    
 Myeloma 3 163    
 MDS / AA 1 128    
Diabetes mellitus    0.040 0.005 0.218(0.076–0.629)
 Yes 10 233    
 No 31 1402    
Allogeneic transplantation    0.116 0.013 0.182(0.047–0.701)
 Yes 15 365    
 No 26 1270    
Liver cirrhosis    <0.001 <0.001 0.002(0.000–0.047)
 Yes 2 8    
 No 39 1627    
Hepatocellular carcinoma    0.748 NA  
 Yes 0 5    
 No 41 1630    
Hepatitis C    0.216 NA  
 Yes 0 65    
 No 41 1570    
Negative Anti-HBs Antibodya    0.237 NA  
 Yes 10 304    
 No 24 1157    
Low Anti-HBs Antibody a    0.002 0.016 0.020(0.001–0.480)
 Yes 30 915    
 No 4 546    
Positive Anti-HBc Antibodyb    0.005 0.013 0.070(0.009–0.571)
 Yes 18 567    
 No 1 263    
  1. NA not available, a Anti-HBs Antibody checked, (n = 1495), Low Anti-HBs Antibody <100mIU/mL, b Anti-HBc Antibody checked (n = 849), AML acute myeloid leukemia, ALL acute lymphoblastic leukemia, CML/MPN chronic myeloid leukemia/myeloproliferative neoplasm, CLL chronic lymphocytic leukemia, MM myeloma, MDS/AA myelodysplastic syndrome/aplastic anemia